
Ablynx has revealed that its interleukin 6 pathway via its IL-6 receptor (IL-6R) vobarilizumab failed to meet its primary endpoint …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

